OR WAIT null SECS
September 17, 2022
When oral acne treatments lead to ocular surface disease, the solution lies in office-based therapies.
September 15, 2022
Janelle Davison, OD, shares highlights from her VEW 2022 presentation, "Intersection of dry eye and beauty: design, build and brand a profitable dry eye spa."
September 10, 2022
Azura has secured funding to support its 2-stage study evaluating the safety, tolerability, and efficacy of AZR-MD-001, its leading candidate, for patients with contact lens discomfort who show signs of meibomian gland dysfunction.
September 07, 2022
Bausch + Lomb and Novaliqu announced that the FDA has accepted its New Drug Application for NOV03, an investigational treatment for dry eye disease associated with meibomian gland dysfunction.
September 06, 2022
FDA-approved steroid offers short-term relief for ocular surface inflammation.
August 25, 2022
Ensure successful symptoms management with your patients.
August 23, 2022
Latest transaction, totaling approximately $770 million, adds key commercial products and clinical/preclinical product candidates in the pipeline.
August 10, 2022
Optometry Times' editor Kassi Jackson speaks with Lauretta Justin, OD, founder of Optometry Divas, and Lisa Hornick, OD, recipient of Optometry Divas' Thought Leader of the Year 2022 award.
August 02, 2022
COMET-3 is the second of 3 studies in the AR-15512 Registrational Phase 3 Program, which is slated for completion by 2023.
July 28, 2022
One OD shares his experience launching a successful social media campaign for Dry Eye Awareness month—and offers 3 tips for crafting a message to capture an audience's attention.
Importance of communication between providers
Unaddressed visual problems negatively impacts safety earnings of workers in underdeveloped countries
What to know about new topical presbyopia-correcting drops
Supplements slow AMD progression, study data confirm
